Blog

Houston company’s immunotherapy treatment gets special FDA status – Chron.com


Chron.com

Houston company's immunotherapy treatment gets special FDA status
Chron.com
Viralym-C is described by its maker as a ready-to-administer T-cell immunotherapy product. In addition to orphan drug designation, the federal agency also granted it Fast Track status, the company said. Orphan drug designation is the special status

2017-01-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.